Cell Signaling

Cells live in a world of messages.

11 frameworks, from 1905 to today · Biology · Natural Sciences

still a working view ended · each leads to its entry below

Overview

Cells live in a world of messages. A bacterium senses sugar and swims toward it; a neuron fires when a signal arrives at its synapse; a liver cell releases glucose when adrenaline reaches it; a dividing cell waits for permission from its neighbours. Cell signaling is the study of how cells detect, transmit, and respond to such information. What is at stake is nothing less than how a body coordinates itself: how a single fertilised egg becomes a patterned organism, how organs adjust to changing demands, and how the same molecular machinery goes wrong in cancer, diabetes, and immune disease1. The field's history is a story of moving from describing that cells respond to their environment to explaining how—through receptors, second messengers, protein switches, and networks—and then discovering that the "how" is far more intricate than any single pathway diagram suggests.

From nerve impulses to chemical transmission

The earliest strand of the field was electrical. In the late eighteenth century, Luigi Galvani showed that electricity could make frog muscles twitch, and by the nineteenth century physiologists had established that nerve signals are electrical events travelling along fibres2. The question of how a signal crosses the gap between one neuron and the next was settled in the early twentieth century. Otto Loewi's 1921 experiment—stimulating a frog heart's vagus nerve and applying the bathing fluid to a second heart, which slowed—demonstrated chemical transmission, later identified as acetylcholine. Henry Dale's work on acetylcholine and other neurotransmitters confirmed that nerves talk to their targets through chemicals. Electrical signalling and chemical signalling were thus recognised as two faces of the same communication problem.

Receptor theory: the idea of a specific receiving molecule

If chemicals carry messages, something on the target cell must receive them. The concept of the receptor emerged from pharmacology rather than biochemistry. In the early twentieth century, Paul Ehrlich proposed that drugs act on specific "side chains" of cells—his corpora non agunt nisi fixata, agents do not act unless they bind. John Newport Langley, studying nicotine and curare on muscle, argued in 1905 for "receptive substances" that combine with drugs. The decisive theoretical step came from A. J. Clark in the 1920s and 1930s, who showed that acetylcholine's effects on heart muscle followed the quantitative law of mass action, as if the drug bound reversibly to a finite number of sites. Clark's dose–response curves gave receptor theory its mathematical shape: response depends on the fraction of receptors occupied.

The theory was refined by E. J. Ariëns, who distinguished affinity (how tightly a drug binds) from intrinsic activity (how well the bound drug activates the receptor), and by R. P. Stephenson, who introduced the idea that a drug need occupy only a fraction of receptors to produce a maximal response—receptor reserve. Later work by Black and Leff formalised this as operational model. For decades the receptor remained a hypothetical entity inferred from pharmacology; its physical isolation would come later.

Second messengers: the signal goes inside

The next turning point was the discovery that a receptor's job is often to trigger a chemical cascade inside the cell. Earl Sutherland, studying how adrenaline makes liver cells release glucose, found in the late 1950s that the hormone raises levels of cyclic AMP (cAMP), a small molecule made from ATP. Sutherland proposed that the hormone binds a receptor on the cell surface, which activates an enzyme—adenylyl cyclase—that produces cAMP, which in turn activates the enzymes that mobilise glucose. cAMP was the first "second messenger": the hormone is the first messenger, cAMP the intracellular relay. Sutherland received the Nobel Prize in 197134.

The concept generalised rapidly. In the 1970s and 1980s, calcium ions were shown to be a second messenger in many contexts, and inositol trisphosphate (IP₃) and diacylglycerol (DAG) were identified by Michael Berridge, Robin Irvine, and others as products of membrane lipid breakdown that mobilise calcium and activate protein kinase C. Cyclic GMP, nitric oxide (shown by Robert Furchgott, Louis Ignarro, and Ferid Murad to relax blood vessels), and lipid messengers such as phosphatidylinositol phosphates joined the list. The second-messenger idea made signalling amplifiable: one hormone molecule can trigger many cAMP molecules, and each can activate many enzymes—a cascade with gain.

G proteins and the seven-transmembrane receptor

How does a receptor activate adenylyl cyclase? The answer came from Alfred Gilman and Martin Rodbell, who in the 1970s and 1980s showed that a guanine-nucleotide-binding protein—a G protein—sits between receptor and enzyme. Rodbell had found that GTP is required for hormone action; Gilman purified the stimulatory G protein, Gs. The receptor itself was cloned in the 1980s: the β-adrenergic receptor, isolated by Robert Lefkowitz's group, turned out to span the membrane seven times. This "seven-transmembrane" architecture defines the largest receptor family in animals, the G protein-coupled receptors (GPCRs). When a ligand binds, the receptor changes shape, activates its G protein by prompting it to exchange GDP for GTP, and the G protein's subunits then act on effectors such as adenylyl cyclase or phospholipase C. Lefkowitz and Brian Kobilka received the Nobel Prize in 2012; Kobilka's later crystal structures of GPCRs showed the conformational change directly.

GPCRs matter because they are the targets of a large share of medicines—antihistamines, beta-blockers, opioids, and many others act through them. The family also includes the light receptor rhodopsin and the olfactory receptors, so the same mechanism underlies vision and smell.

Ion channels and electrical signalling

Running alongside the chemical story was the electrical one, which matured into molecular detail. Alan Hodgkin and Andrew Huxley, working on the squid giant axon in the early 1950s, measured the currents underlying the nerve impulse and proposed that voltage-gated sodium and potassium channels open and close in a voltage-dependent way, producing the action potential. Their quantitative model predicted the shape of the impulse from channel kinetics. The channels themselves were isolated much later: Shaker, the first potassium channel gene, was cloned in the 1980s, and the first ion channel structures were solved in the 1990s and 2000s (Roderick MacKinnon's potassium channel structure in 1998 earned a Nobel Prize in 2003). Ion channels are signalling devices in their own right: they convert chemical or electrical stimuli into ion fluxes, and they underlie synaptic transmission, heartbeat, and sensory transduction. The discovery of channel-linked receptors—such as the nicotinic acetylcholine receptor, a ligand-gated ion channel—connected the chemical and electrical worlds.

Receptor tyrosine kinases and the growth-factor revolution

A different receptor class emerged from cancer research. In the late 1970s and early 1980s, Stanley Cohen and Rita Levi-Montalcini's nerve growth factor and epidermal growth factor (EGF) were shown to act through receptors that are themselves enzymes. The EGF receptor, cloned in the mid-1980s, turned out to have an intracellular kinase domain that phosphorylates tyrosine residues—on itself and on other proteins. This was a new signalling logic: the receptor is a kinase, and ligand binding activates it. The insulin receptor, cloned shortly after, proved to be a tyrosine kinase too, linking this mechanism to metabolism. The discovery that several oncogenes are mutated or overactive versions of receptor tyrosine kinases (and of downstream signalling proteins) tied the field directly to cancer. The human EGF receptor 2 (HER2) became a drug target, and trastuzumab, approved in 1998, was one of the first antibody therapies aimed at a signalling receptor.

Small GTPase switches and kinase cascades

Downstream of these receptors, cells use molecular switches. The Ras proteins, discovered as oncogenes in the early 1980s, are small GTPases: they are "on" when bound to GTP and "off" when bound to GDP, and they relay signals from receptor tyrosine kinases toward the nucleus. Ras mutations are among the most common in human cancer5. The Rho, Rab, and Arf families of small GTPases were later found to control cytoskeletal organisation, membrane traffic, and other processes. The switch logic—a protein that cycles between active and inactive states, regulated by exchange factors and GTPase-activating proteins—became a general motif.

Between receptor and response, cells also deploy kinase cascades: chains of protein kinases in which each kinase activates the next by phosphorylation. The mitogen-activated protein (MAP) kinase cascade, worked out in the 1980s and 1990s, carries signals from Ras to transcription factors; the PI3K–Akt pathway, another major cascade, controls survival and growth. Cascades provide amplification and multiple points of regulation, and their components became prime drug targets (for example, the BRAF inhibitor vemurafenib for melanoma).

Nuclear receptors: signals that enter the cell

Not all receptors sit on the surface. Steroid hormones—oestrogen, testosterone, cortisol—are lipid-soluble and cross the membrane, binding intracellular receptors that act directly as transcription factors. The oestrogen receptor was cloned in 1986, revealing a DNA-binding domain and a hormone-binding domain; the glucocorticoid receptor followed. These nuclear receptors, when bound by hormone, enter the nucleus and switch genes on or off16. The discovery that nuclear receptors are a large family of ligand-regulated transcription factors unified endocrinology with gene regulation, and the receptors became targets for drugs in cancer and metabolic disease (tamoxifen for breast cancer acts through the oestrogen receptor).

Networks, dynamics, and the systems view

By the 1990s, the pathway diagrams had become crowded, and a new question arose: how do these pathways behave as a system? Two developments pushed the field. First, genomics and proteomics made it possible to measure many components at once, and systems biology—using mathematical models and network analysis—began to treat signalling as a dynamic network rather than a set of linear routes. Second, live-cell imaging revealed that signalling is not uniform in space and time. Fluorescent reporters showed that calcium signals oscillate, that Ras activation is transient and localised, and that signalling molecules cluster in microdomains. The field of spatiotemporal signalling grew: the same molecule can produce different outcomes depending on where and when it is active. Scaffold proteins, which hold kinases together in complexes, help explain specificity—why similar cascades produce distinct responses.

The network view also brought feedback and crosstalk to the fore. Pathways that looked separate turned out to regulate each other, and the same kinase could be activated by many inputs. This complexity is now studied with computational models, single-cell measurements, and optogenetic tools that let researchers switch signalling on and off with light.

Where the field stands

Today cell signalling is a sprawling, mature field with several active fronts. Structural biology has resolved many receptors and kinases at atomic detail, guiding drug design. Single-cell and live-imaging methods show that signalling is noisy and heterogeneous even among genetically identical cells. The recognition that many diseases—cancers, immune disorders, metabolic syndromes—are signalling diseases has made the field central to medicine1. Open questions remain: how cells decode the timing and location of signals into specific responses; how signalling networks maintain robustness despite noise; how signals are integrated across scales from molecules to tissues; and how to predict the effect of a drug on a network rather than on a single target. The history of cell signalling is, in a sense, the history of biology learning that communication is not a simple wire but a living, adaptable system.

References

  1. Cell signaling (introduction, Intracellular receptors), Wikipedia
  2. Action potential (History), Wikipedia
  3. Signal transduction (History), Wikipedia
  4. Cyclic adenosine monophosphate (History), Wikipedia
  5. Ras GTPase, Wikipedia
  6. Nuclear receptor, Wikipedia

The frameworks of Cell Signaling

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1905-Present

    Receptor theory

    How do drugs and hormones act on specific cell sites?

    Fly to its tower in Nousfarer

  2. 1921-Present

    Neurotransmission

    How does a signal cross from one neuron to the next?

    Fly to its tower in Nousfarer

  3. 1952-Present

    Ion channel

    How do ions move across membranes to produce electrical signals?

    Fly to its tower in Nousfarer

  4. 1957-Present

    Second messenger system

    How does a surface signal become a chemical change inside the cell?

    Fly to its tower in Nousfarer

  5. 1975-Present

    G protein-coupled receptor

    How does a seven-transmembrane receptor activate an intracellular protein?

    Fly to its tower in Nousfarer

  6. 1980-Present

    Receptor tyrosine kinase

    How do growth factors trigger enzyme activity inside the cell?

    Fly to its tower in Nousfarer

  7. 1982-Present

    Small GTPase

    How do molecular switches cycle between on and off states?

    Fly to its tower in Nousfarer

  8. 1985-Present

    Kinase cascade signalling

    How do chains of kinases relay and amplify a signal?

    Fly to its tower in Nousfarer

  9. 1985-Present

    Nuclear receptor

    How do lipid-soluble signals act directly on gene transcription?

    Fly to its tower in Nousfarer

  10. 1995-Present

    Spatiotemporal signalling

    Where and when inside the cell does a signal act?

    Fly to its tower in Nousfarer

  11. 1995-Present

    Systems and network signalling biology

    How do signalling pathways combine into networks with feedback?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Receptor theoryNeurotransmissionIon channelSecond messenger systemG protein-coupled receptorReceptor tyrosine kinaseSmall GTPaseKinase cascade signallingNuclear receptorSpatiotemporal signallingSystems and network signalling biology

Beyond the field

Where Cell Signaling's ideas came from in other fields, and what they led to there: the strongest 12 of 63 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Cell Signaling is a planet in Nousfarer

Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.

Land on Cell Signaling

Related fields

Fields its ideas are linked to

More in Biology

See where Cell Signaling sits on the Map of Human Knowledge